Status:
UNKNOWN
Treatment of Intrapartum Depression Using Non-invasive Photobiomodulation
Lead Sponsor:
Wayne State University
Conditions:
Depression
Pregnancy Related
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Depression during pregnancy can cause fetal and maternal problems such as growth restriction, preterm labor, low birthweight, poor compliance and suicide. Since antidepressant medications have the pot...
Detailed Description
Depression is common in pregnancy and affects about 70% of women and, for many women, pregnancy can lead to the first episode of major depression. Complications of intrapartum depression include intra...
Eligibility Criteria
Inclusion
- Viable intrauterine pregnancy \<16 weeks, PHQ-9 or Edinburg Score\>10.
Exclusion
- pregnancy \> 20 weeks
- history of seizures
- history of migraines
- history of multiple sclerosis
- prior traumatic brain injury
- prior history of preeclampsia/toxemia
- elevated blood pressure greater than 140/90
- proteinuria (as defined by urine proteins \>300 mg/24 h)
- headaches
- visual changes
- right upper quadrant pain
- history of bipolar disease
- currently taking psychotropic medications (including antidepressants) and
- prior history of attempted suicide
Key Trial Info
Start Date :
November 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04404231
Start Date
November 1 2021
End Date
September 1 2022
Last Update
October 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Detroit Medical Ceter
Detroit, Michigan, United States, 48201